Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

Background Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF
V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving …

Abstract BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We
report the efficacy and safety of dabrafenib plus trametinib in patients with …

BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–
small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF …

Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis
after treatment with cladribine (2CDA), although relapse may occur during follow-up. The …

A significant body of literature has been generated related to the detection of measurable
residual disease (MRD) at the time of achieving complete remission (CR) in patients with …

Simple Summary KRAS and genes in the RAS-MAPK pathway are among the most
frequently deregulated genes in solid tumors and in this context a large amount of KRAS …

Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs
(cladribine and pentostatine). However, approximately half of patients experience 1 or more …

In the category of mature B-cell neoplasms, splenic B-cell lymphoma and leukemia were
clearly identified and include four distinct entities: hairy cell leukemia (HCL), splenic …